Table 2.
Multivariate analysis results concerning FFLR, CFS, FFS, FFDM, and OS.
| Variable | FFLR | CFS | FFS | FFDM | OS | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adj O.R. | 95% C.I. | p | Adj O.R. | 95% C.I. | p | Adj O.R. | 95% C.I. | p | Adj O.R. | 95% C.I. | p | Adj O.R. | 95% C.I. | p | |
| Male sex | 3.5 | 1.7–7.1 | <0.001 | 5.5 | 2–15.1 | 0.001 | 2.1 | 1.01–4.5 | 0,045 | 2.4 | 1.2–4.9 | 0,015 | NS | ||
| True squamous cell carcinoma | 1.4 | 1.1–2.0 | 0.036 | 1.36 | 1.1–2.2 | 0.033 | NS | NS | NS | ||||||
| Tumor fistulization | 4.5 | 1.5–13.4 | 0.006 | 9.8 | 2–48.4 | 0.005 | NS | NS | NS | ||||||
| N+ | NS | NS | NS | 4.9 | 2–12.2 | 0,001 | NS | ||||||||
| High stage group | 2.56 | 1.3–4.9 | 0.006 | NS | NS | NS | |||||||||
| HIV + | NS | NS | NS | NS | NS | ||||||||||
| CDDP-5FU cht | NS | NS | NS | NS | NS | ||||||||||
| Split course schedule | NS | NS | NS | NS | NS | ||||||||||
| Cht compliance | NS | 5.3 | 1.8–17 | 0.003 | NS | NS | NS | ||||||||
| Unplanned treatment interruption | 6.2 | 2.1–17.9 | 0.001 | 80 | 6.7–950 | NS | NS | NS | |||||||
| 2D vs 3D IGRT | 4.5 | 1.9–10.4 | 0.001 | 4.1 | 1.1–14.9 | 0.031 | NS | NS | 5.6 | 1.7–18.1 | 0.01–2 | ||||
| 3DCRT vs IMRT | NS | 3.1 | 0.96–9.9 | 0.059 | NS | NS | 6.6 | 1.5–29.1 | 0.004 | ||||||
3DCRT, 3D conformal radiotherapy; IMRT, intensity modulated radiotherapy; V-MAT, volumetric-modulated ARC therapy; IGRT, image-guided radiotherapy; N+, positive nodes; HIV+, HIV positive; NS, not statistically signficant.